Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fabrazyme Approved; FDA Weighing What Confirmatory Data Will Be Needed

Executive Summary

FDA has set a deadline of Jan. 31, 2004 for Genzyme's Fabrazyme confirmatory placebo-controlled trial following its April 24 approval

You may also be interested in...



Replagal Advisory Committee Will Include Closed Door Session On Manufacturing

FDA’s Cardiovascular and Renal Drugs Advisory Committee will assess Shire biologics’ BLA for the Fabry disease therapy, which already is available in the U.S. due to shortages of competitor Fabrazyme, during a March 27 meeting.

Insmed Seeks To Block Tercica Growth Hormone In Orphan Exclusivity Fight

A battle for orphan drug exclusivity may be at the heart of a dispute between Insmed and Tercica over the companies' pending NDAs for growth hormone treatments

Insmed Seeks To Block Tercica Growth Hormone In Orphan Exclusivity Fight

A battle for orphan drug exclusivity may be at the heart of a dispute between Insmed and Tercica over the companies' pending NDAs for growth hormone treatments

Related Content

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel